Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001346824-26-000072
Filing Date
2026-03-11
Accepted
2026-03-11 16:43:17
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 15148
  Complete submission text file 0001346824-26-000072.txt   17064
Mailing Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116
Business Address 200 BERKELEY STREET, 18TH FLOOR BOSTON MA 02116 617-778-2500
RA CAPITAL MANAGEMENT, L.P. (Filed by) CIK: 0001346824 (see all company filings)

EIN.: 830406777 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Subject) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-92283 | Film No.: 26744058
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)